Foundation Medicine, QED Therapeutics to Develop CDx for Bile Duct Cancer

Dec 10, 2018

|

NEW YORK (GenomeWeb) – QED Therapeutics said today that it has partnered with Foundation Medicine to develop a companion diagnostic for its drug candidate infigratinib in patients with cholangiocarcinoma (bile duct cancer).

Infigratinib is an FGFR1-3-selective tyrosine kinase inhibitor, and the CDx will include the detection of activating FGFR2 fusions. It is expected to be incorporated into FoundationOne CDx, Foundation Medicine's FDA-approved comprehensive genomic profiling assay for all solid tumors, which includes several companion diagnostics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Mysterious Third Group

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

This Week in Science

In Science this week: reduction in bee phylogenetic diversity, and more.

In the Past

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

New Bases, New Drugs

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.

Feb

21

Featured Webinar

Case Study: 'Companion Informatics' to Automate Immunotherapy Manufacturing and Treatment

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.

Feb

26

Featured Webinar

A Cellular and Molecular Phenotyping Pipeline for Target Characterization in FFPE Biobank Samples

This webinar will demonstrate how a research team at the Firestone Institute for Respiratory Health at McMaster University developed a cellular and molecular phenotyping pipeline using archived samples of lung tissue derived from patients diagnosed with fibrotic interstitial lung disease.

Main menu